Key facts
- It has raised $13.6M; the latest was Seed Round ($13.6M) in Jan 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Mighto Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mighto Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mighto Therapeutics
Operator of a biotech company intended to develop disease-modifying therapies for mitochondrial and neurodegenerative disorders. The company offers first-in-class oral small-molecule therapeutics that reverse mitochondrial DNA defects and enhance metabolic and respiratory function, enabling patients with currently untreatable conditions such as MELAS, Parkinson's disease and Lewy body dementia to access transformative care beyond the limitations of standard-of-care treatments.
- Sector
- Healthcare
- HQ
- Hamburg, Germany
- Founded
- 2025
- Website
- mightotx.com/
- Ownership
- Privately Held (backing)
Mighto Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mighto Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mighto Therapeutics in its N-PORT filings yet. We sweep new filings monthly.